Catalyst Wire Dossier Catalyst Wire Dossier

AP611074 5% Gel

AP611074 · Vaxart, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AP611074 5% Gel, covering 2018-07-20 to 2018-07-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients [Phase 2]

See pricing